<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230828060912&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230828060912&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Mon, 28 Aug 2023 10:09:14 +0000</lastbuilddate>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Dapagliflozin in Patients with Heart Failure and Deterioration in Estimated Glomerular Filtration Rate to &amp;lt;25ml/min/1.73m&lt;sup>;2&lt;/sup>;</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634707/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Patients with deterioration of kidney function below eGFR 25ml/min/1.73m² had elevated risks of CV outcomes yet appeared to benefit from continuation of dapagliflozin with no excess in safety outcomes between treatment groups. The benefit-to-risk ratio may favor continuation of dapagliflozin treatment in patients with HF experiencing deterioration of kidney function.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 23:S0735-1097(23)06532-4. doi: 10.1016/j.jacc.2023.08.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: SGLT-2 inhibitors are guideline-recommended in the management of heart failure(HF). While these therapies can be initiated even in patients with comorbid CKD, some patients may face deterioration in kidney function over time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To examine the safety and efficacy of continuing SGLT-2 inhibitors in HF when eGFR falls below thresholds for initiation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Associations between a deterioration in eGFR below 25 ml/min/1.73m<sup>2</sup> , efficacy and safety outcomes, and treatment with dapagliflozin were evaluated in time-updated Cox proportional hazards models in a participant-level pooled analysis of DAPA-HF and DELIVER.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 11,007 patients, 347 (3.2%) experienced a deterioration in eGFR to &lt;25ml/min/1.73m<sup>2</sup> at least once in follow-up. These patients had a higher risk of the primary composite outcome (HR 1.87; 95% CI: 1.48-2.35, p&lt;0.001). The risk of the primary outcome was lower with dapagliflozin compared with placebo both among patients who did (HR 0.53; 95% CI: 0.33-0.83) and did not (HR 0.78; 95% CI: 0.72-0.86) experience deterioration in kidney function below eGFR&lt;25ml/min/1.73m<sup>2</sup> (P<sub>interaction</sub>=0.17). The risk of safety outcomes including drug discontinuation were higher among patients with deterioration in eGFR&lt;25ml/min/1.73m<sup>2</sup> ; however, rates remained similar between treatment groups including among those who remained on study drug.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with deterioration of kidney function below eGFR 25ml/min/1.73m<sup>2</sup> had elevated risks of CV outcomes yet appeared to benefit from continuation of dapagliflozin with no excess in safety outcomes between treatment groups. The benefit-to-risk ratio may favor continuation of dapagliflozin treatment in patients with HF experiencing deterioration of kidney function.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634707/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37634707</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.026>10.1016/j.jacc.2023.08.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634707</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Finnian R Mc Causland</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Felipe A Martinez</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Lars Kober</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Bela Merkely</dc:creator>
<dc:creator>Magnus Petersson</dc:creator>
<dc:creator>Anna Maria Langkilde</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Dapagliflozin in Patients with Heart Failure and Deterioration in Estimated Glomerular Filtration Rate to &amp;lt;25ml/min/1.73m&lt;sup>;2&lt;/sup>;</dc:title>
<dc:identifier>pmid:37634707</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.026</dc:identifier>
</item>
<item>
<title>Coronary Flow Capacity And Survival Prediction After Revascularization: Physiological Basis And Clinical Implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Severely reduced CFC and associated Observed survival probability improved after first and repeat revascularization compared with no revascularization for comparable CFC severity. Non-severe CFC showed no benefit. Discordance between Observed actual and Virtual hypothetical post=revascularization survival probability revealed residual CAD or failed revascularization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad579. doi: 10.1093/eurheartj/ehad579. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Coronary Flow Capacity (CFC) associates with an Observed 10-yearsurvival probability for individual patients before and after actual revascularization for comparison to Virtual hypothetical ideal complete revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Stress myocardial perfusion (mL/min/g) and coronary flow reserve (CFR) per pixel were quantified in 6979 coronary artery disease (CAD) subjects using Rb-82 positron emission tomography (PET) for CFC maps of artery-specific size-severity abnormalities expressed as percent left ventricle (%LV) with prospective follow-up to define survival probability per-decade as fraction of 1.0.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Severely reduced CFC in 6979 subjects predicted low survival probability that improved by 42% after revascularization compared with no revascularization for comparable severity (P=0.0015). For 283 pre-and-post-procedure PET pairs, severely reduced regional CFC-associated survival probability improved heterogeneously after revascularization (P&lt;0.001), more so after bypass surgery than percutaneous coronary interventions (P&lt;0.001) but normalized in only 5.7%; non-severe baseline CFC or survival probability did not improve compared with severe CFC (P=0.00001). Observed CFC=associated survival probability after actual revascularization was lower than Virtual ideal hypothetical complete post-revascularization survival probability due to residual CAD or failed revascularization (P&lt;0.001) unrelated to gender or microvascular dysfunction. Severely reduced CFC in 2552 post-revascularization subjects associated with low survival probability also improved after repeat revascularization compared with no repeat procedures (P=0.025).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Severely reduced CFC and associated Observed survival probability improved after first and repeat revascularization compared with no revascularization for comparable CFC severity. Non-severe CFC showed no benefit. Discordance between Observed actual and Virtual hypothetical post=revascularization survival probability revealed residual CAD or failed revascularization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37634192</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad579>10.1093/eurheartj/ehad579</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634192</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>K Lance Gould</dc:creator>
<dc:creator>Nils P Johnson</dc:creator>
<dc:creator>Amanda E Roby</dc:creator>
<dc:creator>Linh Bui</dc:creator>
<dc:creator>Danai Kitkungvan</dc:creator>
<dc:creator>Monica B Patel</dc:creator>
<dc:creator>Tung Nguyen</dc:creator>
<dc:creator>Richard Kirkeeide</dc:creator>
<dc:creator>Mary Haynie</dc:creator>
<dc:creator>Salman A Arain</dc:creator>
<dc:creator>Konstantinos Charitakis</dc:creator>
<dc:creator>Abhijeet Dhoble</dc:creator>
<dc:creator>Richard Smalling</dc:creator>
<dc:creator>Angelo Nascimbene</dc:creator>
<dc:creator>Marwan Jumean</dc:creator>
<dc:creator>Sachin Kumar</dc:creator>
<dc:creator>Biswajit Kar</dc:creator>
<dc:creator>Stefano Sdringola</dc:creator>
<dc:creator>Anthony Estrera</dc:creator>
<dc:creator>Igor Gregoricm</dc:creator>
<dc:creator>Dejian Lai</dc:creator>
<dc:creator>Ruosha Li</dc:creator>
<dc:creator>David McPherson</dc:creator>
<dc:creator>Jagat Narula</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary Flow Capacity And Survival Prediction After Revascularization: Physiological Basis And Clinical Implications</dc:title>
<dc:identifier>pmid:37634192</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad579</dc:identifier>
</item>
<item>
<title>Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement (TAVR-CMR): A Randomized, Open-Label, Non-Inferiority Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>Background: Computed tomography (CT) is recommended for guiding transcatheter aortic valve replacement (TAVR). However, as a sizable proportion of TAVR candidates have chronic kidney disease (CKD), the use of iodinated contrast media is a limitation. Cardiac magnetic resonance (CMR) is a promising alternative, yet randomized data comparing the effectiveness of CMR- versus CT-guided TAVR are lacking. Methods: An investigator-initiated, prospective, randomized, open-label, non-inferiority trial...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 27. doi: 10.1161/CIRCULATIONAHA.123.066498. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Computed tomography (CT) is recommended for guiding transcatheter aortic valve replacement (TAVR). However, as a sizable proportion of TAVR candidates have chronic kidney disease (CKD), the use of iodinated contrast media is a limitation. Cardiac magnetic resonance (CMR) is a promising alternative, yet randomized data comparing the effectiveness of CMR- versus CT-guided TAVR are lacking. <b>Methods:</b> An investigator-initiated, prospective, randomized, open-label, non-inferiority trial was conducted at two Austrian heart centers. Patients evaluated for TAVR according to the inclusion (severe symptomatic aortic stenosis) and exclusion criteria (contraindication to CMR, CT, or TAVR, a life expectancy &lt; 1 year, CKD 4 or 5) were randomized (1:1) to undergo CMR- or CT-guiding. The primary outcome was defined according to the Valve Academic Research Consortium-2 definition of implantation success at discharge, including absence of procedural mortality, correct positioning of a single prosthetic valve, and proper prosthetic valve performance. Non-inferiority was assessed using a hybrid modified intention-to-treat (mITT)/per-protocol (PP) approach based on an absolute risk difference margin of 9%. <b>Results:</b> Between September 11, 2017, and December 16, 2022, 380 candidates for TAVR were randomized to CMR-guided (191 patients) or CT-guided (189 patients) TAVR planning. Of these, 138 patients (72.3%) in the CMR-guided group and 129 patients (68.3%) in the CT-guided group eventually underwent TAVR (mITT cohort). Of these 267, 19 patients had protocol deviations, resulting in a PP cohort of 248 patients (n=121 CMR-guided, n=127 CT-guided). In the mITT cohort, implantation success was achieved in 129 patients (93.5%) in the CMR group and in 117 patients (90.7%) in the CT group (between-group difference, 2.8%; 90% confidence interval [CI]: -2.7 to 8.2%; p&lt;0.01 for non-inferiority). In the PP cohort (n=248), the between-group difference was 2.0% (90% CI: -3.8 to 7.8%; p&lt;0.01 for non-inferiority). <b>Conclusions:</b> CMR-guided TAVR was non-inferior to CT-guided TAVR in terms of device implantation success. CMR can therefore be considered as an alternative for TAVR planning.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37634187</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066498>10.1161/CIRCULATIONAHA.123.066498</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634187</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Martin Reindl</dc:creator>
<dc:creator>Ivan Lechner</dc:creator>
<dc:creator>Magdalena Holzknecht</dc:creator>
<dc:creator>Christina Tiller</dc:creator>
<dc:creator>Priscilla Fink</dc:creator>
<dc:creator>Fritz Oberhollenzer</dc:creator>
<dc:creator>Sebastian von der Emde</dc:creator>
<dc:creator>Mathias Pamminger</dc:creator>
<dc:creator>Felix Troger</dc:creator>
<dc:creator>Christian Kremser</dc:creator>
<dc:creator>Elisabeth Laßnig</dc:creator>
<dc:creator>Kathrin Danninger</dc:creator>
<dc:creator>Ronald K Binder</dc:creator>
<dc:creator>Hanno Ulmer</dc:creator>
<dc:creator>Christoph Brenner</dc:creator>
<dc:creator>Gert Klug</dc:creator>
<dc:creator>Axel Bauer</dc:creator>
<dc:creator>Bernhard Metzler</dc:creator>
<dc:creator>Agnes Mayr</dc:creator>
<dc:creator>Sebastian Johannes Reinstadler</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement (TAVR-CMR): A Randomized, Open-Label, Non-Inferiority Trial</dc:title>
<dc:identifier>pmid:37634187</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066498</dc:identifier>
</item>
<item>
<title>Instantaneous wave-free ratio compared to fractional flow reserve: time for rethinking current recommendations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634167/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad574. doi: 10.1093/eurheartj/ehad574. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634167/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37634167</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad574>10.1093/eurheartj/ehad574</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634167</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mirvat Alasnag</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Instantaneous wave-free ratio compared to fractional flow reserve: time for rethinking current recommendations</dc:title>
<dc:identifier>pmid:37634167</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad574</dc:identifier>
</item>
<item>
<title>Coronary revascularization guided by instantaneous wave-free ratio compared to fractional flow reserve: pooled 5-year mortality in the DEFINE-FLAIR and iFR-SWEDEHEART trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634165/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad552. doi: 10.1093/eurheartj/ehad552. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634165/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37634165</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad552>10.1093/eurheartj/ehad552</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634165</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Colin Berry</dc:creator>
<dc:creator>John D McClure</dc:creator>
<dc:creator>Keith G Oldroyd</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary revascularization guided by instantaneous wave-free ratio compared to fractional flow reserve: pooled 5-year mortality in the DEFINE-FLAIR and iFR-SWEDEHEART trials</dc:title>
<dc:identifier>pmid:37634165</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad552</dc:identifier>
</item>
<item>
<title>New-onset atrial fibrillation in chronic coronary syndrome: the CLARIFY registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Among CCS patients, NOAF is common and is strongly associated with worse outcomes. Whether more intensive preventive measures and more systematic screening for AF would improve prognosis in this population deserves further investigation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad556. doi: 10.1093/eurheartj/ehad556. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Data on new-onset atrial fibrillation (NOAF) in patients with chronic coronary syndromes (CCS) are scarce. This study aims to describe the incidence, predictors and impact on cardiovascular outcomes of NOAF in CCS patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data from the international (45 countries) CLARIFY registry (prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) were used. Among 29,001 CCS outpatients without previously reported AF at baseline, patients with at least one episode of AF/flutter diagnosed during 5-year follow-up were compared with patients in sinus rhythm throughout the study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The incidence rate of NOAF was 1.12 [95% confidence interval (CI) 1.06-1.18] per 100 patient-years (cumulative incidence at 5 years: 5.0%). Independent predictors of NOAF were increasing age, increasing body mass index, low estimated glomerular filtration rate, Caucasian ethnicity, alcohol intake and low left ventricular ejection fraction, while high triglycerides were associated with lower incidence. NOAF was associated with a substantial increase in the risk of adverse outcomes, with adjusted hazard ratios of 2.01 (95% CI 1.61-2.52) for the composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, 2.61 (95% CI 2.04-3.34) for cardiovascular death, 1.64 (95% CI 1.07-2.50) for non-fatal myocardial infarction, 2.27 (95% CI 1.85-2.78) for all-cause death, 8.44 (95% CI 7.05-10.10) for hospitalization for heart failure and 4.46 (95% CI 2.85-6.99) for major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among CCS patients, NOAF is common and is strongly associated with worse outcomes. Whether more intensive preventive measures and more systematic screening for AF would improve prognosis in this population deserves further investigation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37634147</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad556>10.1093/eurheartj/ehad556</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634147</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Alexandre Gautier</dc:creator>
<dc:creator>Fabien Picard</dc:creator>
<dc:creator>Gregory Ducrocq</dc:creator>
<dc:creator>Yedid Elbez</dc:creator>
<dc:creator>Kim M Fox</dc:creator>
<dc:creator>Roberto Ferrari</dc:creator>
<dc:creator>Ian Ford</dc:creator>
<dc:creator>Jean-Claude Tardif</dc:creator>
<dc:creator>Michal Tendera</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New-onset atrial fibrillation in chronic coronary syndrome: the CLARIFY registry</dc:title>
<dc:identifier>pmid:37634147</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad556</dc:identifier>
</item>
<item>
<title>Five-year major cardiovascular events are increased when coronary revascularization is guided by instantaneous wave-free ratio compared to fractional flow reserve: a pooled analysis of iFR-SWEDEHEART and DEFINE-FLAIR trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634144/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Five-year all-cause mortality and MACE rates were increased with revascularization guided by iFR compared to FFR. Rates of unplanned revascularization and MI were equal in the two groups.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad582. doi: 10.1093/eurheartj/ehad582. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Guidelines recommend revascularization of intermediate epicardial artery stenosis to be guided by evidence of ischemia. Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are equally recommended. Individual 5-year results of two major randomized trials comparing FFR with iFR-guided revascularization suggested increased all-cause mortality following iFR-guided revascularization. The aim of this study was a study-level meta-analysis of the 5-year outcome data in iFR-SWEDEHEART (NCT02166736) and DEFINE-FLAIR (NCT02053038).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Composite of major adverse cardiovascular events (MACE) and its individual components [all-cause death, myocardial infarction (MI), and unplanned revascularisation] were analysed. Raw Kaplan-Meier estimates, numbers at risk and number of events were extracted at 5-year follow-up and analysed using the ipdfc package (Stata version 18, StataCorp College Station, TX USA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, iFR and FFR-guided revascularization was performed in 2,254 and 2,257 patients, respectively. Revascularization was more often deferred in the iFR-group [n = 1,128 (50.0 %)] vs. the FFR-group [n = 1021 (45.2 %); p=0.001]. In the iFR-guided group the number of deaths, MACE, unplanned revascularization, and MI were 188 (8.3%), 484 (21.5%), 235 (10.4%), and 123 (5.5%) vs. 143 (6.3%), 420 (18.6%), 241 (10.7%), and 123 (5.4%) in the FFR-group. Hazard ratio [95% confidence interval (CI)] estimates for MACE were 1.18 [1.035; 1.34], all-cause mortality 1.34 [1.08; 1.67], unplanned revascularization 0.99 [0.83; 1.19], and MI 1.02 [0.80; 1.32].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Five-year all-cause mortality and MACE rates were increased with revascularization guided by iFR compared to FFR. Rates of unplanned revascularization and MI were equal in the two groups.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634144/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37634144</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad582>10.1093/eurheartj/ehad582</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634144</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ashkan Eftekhari</dc:creator>
<dc:creator>Emil Nielsen Holck</dc:creator>
<dc:creator>Jelmer Westra</dc:creator>
<dc:creator>Niels Thue Olsen</dc:creator>
<dc:creator>Niels Henrik Bruun</dc:creator>
<dc:creator>Lisette Okkels Jensen</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Evald Høj Christiansen</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Five-year major cardiovascular events are increased when coronary revascularization is guided by instantaneous wave-free ratio compared to fractional flow reserve: a pooled analysis of iFR-SWEDEHEART and DEFINE-FLAIR trials</dc:title>
<dc:identifier>pmid:37634144</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad582</dc:identifier>
</item>
<item>
<title>Critical limb-threatening ischemia and microvascular transformation: clinical implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634134/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These findings depict a progressive, hypoxia-driven transformation of the microvasculature in CLTI muscles, which pathologically alters blood flow dynamics and aggravates tissue damage under low arterial driving pressure. Hypoxia-driven capillary enlargement can be highly important for CLTI outcomes and should therefore be considered in further development of diagnostics and treatment of CLTI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad562. doi: 10.1093/eurheartj/ehad562. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Clinical management of critical limb-threatening ischemia (CLTI) is focused on prevention and treatment of atherosclerotic arterial occlusions. The role of microvascular pathology in disease progression is still largely unspecified and more importantly not utilized for treatment. The aim of this explorative study was to characterize the role of the microvasculature in CLTI pathology.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Clinical high-resolution imaging of CLTI patients (n=50) and muscle samples from amputated CLTI limbs (n=40) were used to describe microvascular pathology of CLTI at the level of resting muscle blood flow and microvascular structure, respectively. Furthermore, a chronic, low arterial driving pressure-simulating ischemia model in rabbits (n=24) was used together with adenoviral vascular endothelial growth factor A gene transfers to study the effect of microvascular alterations on muscle outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Resting microvascular blood flow was not depleted but displayed decreased capillary transit time (P&lt;0.01) in CLTI muscles. CLTI muscle microvasculature also exhibited capillary enlargement (P&lt;0.001) and further arterialization along worsening of myofiber atrophy and detaching of capillaries from myofibers. Furthermore, CLTI-like capillary transformation was shown to worsen calf muscle force production (P&lt;0.05) and tissue outcome (P&lt;0.01) under chronic ischemia in rabbits and in healthy, normal rabbit muscle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings depict a progressive, hypoxia-driven transformation of the microvasculature in CLTI muscles, which pathologically alters blood flow dynamics and aggravates tissue damage under low arterial driving pressure. Hypoxia-driven capillary enlargement can be highly important for CLTI outcomes and should therefore be considered in further development of diagnostics and treatment of CLTI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634134/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37634134</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad562>10.1093/eurheartj/ehad562</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634134</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Santeri Tarvainen</dc:creator>
<dc:creator>Galina Wirth</dc:creator>
<dc:creator>Greta Juusola</dc:creator>
<dc:creator>Olli Hautero</dc:creator>
<dc:creator>Kari Kalliokoski</dc:creator>
<dc:creator>Tanja Sjöros</dc:creator>
<dc:creator>Veikko Nikulainen</dc:creator>
<dc:creator>Jouni Taavitsainen</dc:creator>
<dc:creator>Jarkko Hytönen</dc:creator>
<dc:creator>Crister Frimodig</dc:creator>
<dc:creator>Krista Happonen</dc:creator>
<dc:creator>Tuomas Selander</dc:creator>
<dc:creator>Tomi Laitinen</dc:creator>
<dc:creator>Harri H Hakovirta</dc:creator>
<dc:creator>Juhani Knuuti</dc:creator>
<dc:creator>Nihay Laham-Karam</dc:creator>
<dc:creator>Juha Hartikainen</dc:creator>
<dc:creator>Kimmo Mäkinen</dc:creator>
<dc:creator>Seppo Ylä-Herttuala</dc:creator>
<dc:creator>Petra Korpisalo</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Critical limb-threatening ischemia and microvascular transformation: clinical implications</dc:title>
<dc:identifier>pmid:37634134</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad562</dc:identifier>
</item>
<item>
<title>Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634130/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>Background: There is ambiguity whether frail patients with atrial fibrillation (AF) managed with vitamin K antagonists (VKAs) should be switched to a non-vitamin K oral anticoagulant (NOAC). Methods: We conducted a pragmatic, multicenter, open-label, randomized controlled superiority trial. Older AF patients living with frailty (age ≥75 years plus a Groningen Frailty Indicator (GFI) score ≥3) were randomized to switch from INR-guided VKA treatment to a NOAC or to continued VKA treatment....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 27. doi: 10.1161/CIRCULATIONAHA.123.066485. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> There is ambiguity whether frail patients with atrial fibrillation (AF) managed with vitamin K antagonists (VKAs) should be switched to a non-vitamin K oral anticoagulant (NOAC). <b>Methods:</b> We conducted a pragmatic, multicenter, open-label, randomized controlled superiority trial. Older AF patients living with frailty (age ≥75 years plus a Groningen Frailty Indicator (GFI) score ≥3) were randomized to switch from INR-guided VKA treatment to a NOAC or to continued VKA treatment. Patients with a glomerular filtration rate &lt;30 mL/min/1.73 m<sup>2</sup> or with valvular AF were excluded. Follow-up was 12 months. The cause-specific hazard ratio (HR) was calculated for occurrence of the primary outcome which was a major or clinically relevant non-major bleeding complication, whichever came first, accounting for death as a competing risk. Analyses followed the intention-to-treat principle. Secondary outcomes included thromboembolic events. <b>Results:</b> Between January 2018 and June 2022, a total of 2,621 patients were screened for eligibility and 1,330 patients were randomized (mean age 83 years, median GFI 4). After randomization 6 patients in the switch to NOAC arm and 1 patient in the continue with VKA arm were excluded due to the presence of exclusion criteria, leaving 662 patients switched from a VKA to a NOAC and 661 patients continued VKAs in the intention-to-treat population. After 163 primary outcome events (101 in the switch arm, 62 in the continue arm), the trial was stopped for futility according to a prespecified futility analysis. The HR for our primary outcome was 1.69 (95% CI 1.23-2.32). The HR for thromboembolic events was 1.26 (95% CI 0.60 to 2.61). <b>Conclusions:</b> Switching INR-guided VKA treatment to a NOAC in frail older patients with AF was associated with more bleeding complications compared to continuing VKA treatment, without an associated reduction in thromboembolic complications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634130/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37634130</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066485>10.1161/CIRCULATIONAHA.123.066485</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634130</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Linda P T Joosten</dc:creator>
<dc:creator>Sander van Doorn</dc:creator>
<dc:creator>Peter M van de Ven</dc:creator>
<dc:creator>Bart T G Köhlen</dc:creator>
<dc:creator>Melchior C Nierman</dc:creator>
<dc:creator>Huiberdina L Koek</dc:creator>
<dc:creator>Martin E W Hemels</dc:creator>
<dc:creator>Menno V Huisman</dc:creator>
<dc:creator>Marieke Kruip</dc:creator>
<dc:creator>Laura M Faber</dc:creator>
<dc:creator>Nynke M Wiersma</dc:creator>
<dc:creator>Wim F Buding</dc:creator>
<dc:creator>Rob Fijnheer</dc:creator>
<dc:creator>Henk J Adriaansen</dc:creator>
<dc:creator>Kit C Roes</dc:creator>
<dc:creator>Arno W Hoes</dc:creator>
<dc:creator>Frans H Rutten</dc:creator>
<dc:creator>Geert-Jan Geersing</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:37634130</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066485</dc:identifier>
</item>
<item>
<title>Biventricular Arrhythmogenic Cardiomyopathy: 12-Year Natural History</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634129/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad554. doi: 10.1093/eurheartj/ehad554. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634129/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37634129</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad554>10.1093/eurheartj/ehad554</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634129</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Maria Cristina Procopio</dc:creator>
<dc:creator>Francisco Alpedurada</dc:creator>
<dc:creator>Chiara Bucciarelli-Ducci</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Biventricular Arrhythmogenic Cardiomyopathy: 12-Year Natural History</dc:title>
<dc:identifier>pmid:37634129</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad554</dc:identifier>
</item>
<item>
<title>Optical Coherence Tomography-Guided or Intravascular Ultrasound Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634092/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>Background: Intravascular imaging-guided percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) or optical coherence tomography (OCT) showed superior clinical outcomes compared to angiography-guided PCI. However, comparative effectiveness of OCT-guided and IVUS-guided PCI regarding clinical outcomes is unknown. Methods: In this prospective, multicenter, open-label, pragmatic trial, we randomly assigned 2008 patients with significant coronary-artery lesions undergoing PCI...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 27. doi: 10.1161/CIRCULATIONAHA.123.066429. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Intravascular imaging-guided percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) or optical coherence tomography (OCT) showed superior clinical outcomes compared to angiography-guided PCI. However, comparative effectiveness of OCT-guided and IVUS-guided PCI regarding clinical outcomes is unknown. <b>Methods:</b> In this prospective, multicenter, open-label, pragmatic trial, we randomly assigned 2008 patients with significant coronary-artery lesions undergoing PCI in a 1:1 ratio to undergo either an OCT-guided or IVUS-guided PCI. The primary end point was a composite of death from cardiac causes, target-vessel-related myocardial infarction, or ischemia-driven target-vessel revascularization at 1 year, which was powered for noninferiority of the OCT group as compared with the IVUS group. Safety outcomes were also assessed. <b>Results:</b> At 1 year, primary end-point events occurred in 25 of 1005 patients (Kaplan-Meier estimate, 2.5%) in the OCT group and in 31 of 1003 patients (Kaplan-Meier estimate, 3.1%) in the IVUS group (absolute difference, -0.6 percentage points; upper boundary of one-sided 97.5% confidence interval, 0.97 percentage points; P&lt;0.001 for noninferiority). The incidence of contrast-induced nephropathy was similar (14 patients [1.4%] in the OCT group vs. 15 patients [1.5%] in the IVUS group, P=0.85). The incidence of major procedural complications was lower in the OCT group than in the IVUS group (22 [2.2%] vs. 37 [3.7%], P=0.047), although imaging procedure-related complications were not observed. <b>Conclusions:</b> In patients with significant coronary-artery lesions, OCT-guided PCI was noninferior to IVUS-guided PCI with respect to the incidence of a composite of death from cardiac causes, target-vessel-related myocardial infarction, or ischemia-driven target-vessel revascularization at 1 year. The selected study population and lower than expected event rates should be considered in interpreting the trial.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634092/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37634092</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066429>10.1161/CIRCULATIONAHA.123.066429</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634092</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Do-Yoon Kang</dc:creator>
<dc:creator>Jung-Min Ahn</dc:creator>
<dc:creator>Sung-Cheol Yun</dc:creator>
<dc:creator>Seung Ho Hur</dc:creator>
<dc:creator>Yun-Kyeong Cho</dc:creator>
<dc:creator>Cheol Hyun Lee</dc:creator>
<dc:creator>Soon Jun Hong</dc:creator>
<dc:creator>Subin Lim</dc:creator>
<dc:creator>Sang-Wook Kim</dc:creator>
<dc:creator>Hoyoun Won</dc:creator>
<dc:creator>Jun-Hyok Oh</dc:creator>
<dc:creator>Jeong Cheon Choe</dc:creator>
<dc:creator>Young Joon Hong</dc:creator>
<dc:creator>Yong-Hoon Yoon</dc:creator>
<dc:creator>Hoyun Kim</dc:creator>
<dc:creator>Yeonwoo Choi</dc:creator>
<dc:creator>Jinho Lee</dc:creator>
<dc:creator>Young Won Yoon</dc:creator>
<dc:creator>Soo-Joong Kim</dc:creator>
<dc:creator>Jang Ho Bae</dc:creator>
<dc:creator>Duk-Woo Park</dc:creator>
<dc:creator>Seung-Jung Park</dc:creator>
<dc:creator>OCTIVUS Investigators</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Optical Coherence Tomography-Guided or Intravascular Ultrasound Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37634092</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066429</dc:identifier>
</item>
<item>
<title>Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37633268/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>Thrombopoietin (THPO or TPO) is an essential cytokine for hematopoietic stem cell (HSC) maintenance and megakaryocyte differentiation. Here, we report the 3.4 Å resolution cryoelectron microscopy structure of the extracellular TPO-TPO receptor (TpoR or MPL) signaling complex, revealing the basis for homodimeric MPL activation and providing a structural rationalization for genetic loss-of-function thrombocytopenia mutations. The structure guided the engineering of TPO variants (TPO^(mod)) with a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 22:S0092-8674(23)00852-8. doi: 10.1016/j.cell.2023.07.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Thrombopoietin (THPO or TPO) is an essential cytokine for hematopoietic stem cell (HSC) maintenance and megakaryocyte differentiation. Here, we report the 3.4 Å resolution cryoelectron microscopy structure of the extracellular TPO-TPO receptor (TpoR or MPL) signaling complex, revealing the basis for homodimeric MPL activation and providing a structural rationalization for genetic loss-of-function thrombocytopenia mutations. The structure guided the engineering of TPO variants (TPO<sup>mod</sup>) with a spectrum of signaling activities, from neutral antagonists to partial- and super-agonists. Partial agonist TPO<sup>mod</sup> decoupled JAK/STAT from ERK/AKT/CREB activation, driving a bias for megakaryopoiesis and platelet production without causing significant HSC expansion in mice and showing superior maintenance of human HSCs in vitro. These data demonstrate the functional uncoupling of the two primary roles of TPO, highlighting the potential utility of TPO<sup>mod</sup> in hematology research and clinical HSC transplantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37633268/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37633268</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.037>10.1016/j.cell.2023.07.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37633268</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Naotaka Tsutsumi</dc:creator>
<dc:creator>Zahra Masoumi</dc:creator>
<dc:creator>Sophie C James</dc:creator>
<dc:creator>Julie A Tucker</dc:creator>
<dc:creator>Hauke Winkelmann</dc:creator>
<dc:creator>William Grey</dc:creator>
<dc:creator>Lora K Picton</dc:creator>
<dc:creator>Lucie Moss</dc:creator>
<dc:creator>Steven C Wilson</dc:creator>
<dc:creator>Nathanael A Caveney</dc:creator>
<dc:creator>Kevin M Jude</dc:creator>
<dc:creator>Cornelius Gati</dc:creator>
<dc:creator>Jacob Piehler</dc:creator>
<dc:creator>Ian S Hitchcock</dc:creator>
<dc:creator>K Christopher Garcia</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis</dc:title>
<dc:identifier>pmid:37633268</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.037</dc:identifier>
</item>
<item>
<title>PINK1, Keap1, and Rtnl1 regulate selective clearance of endoplasmic reticulum during development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37633267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>Selective clearance of organelles, including endoplasmic reticulum (ER) and mitochondria, by autophagy plays an important role in cell health. Here, we describe a developmentally programmed selective ER clearance by autophagy. We show that Parkinson's disease-associated PINK1, as well as Atl, Rtnl1, and Trp1 receptors, regulate ER clearance by autophagy. The E3 ubiquitin ligase Parkin functions downstream of PINK1 and is required for mitochondrial clearance while having the opposite function in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 21:S0092-8674(23)00862-0. doi: 10.1016/j.cell.2023.08.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Selective clearance of organelles, including endoplasmic reticulum (ER) and mitochondria, by autophagy plays an important role in cell health. Here, we describe a developmentally programmed selective ER clearance by autophagy. We show that Parkinson's disease-associated PINK1, as well as Atl, Rtnl1, and Trp1 receptors, regulate ER clearance by autophagy. The E3 ubiquitin ligase Parkin functions downstream of PINK1 and is required for mitochondrial clearance while having the opposite function in ER clearance. By contrast, Keap1 and the E3 ubiquitin ligase Cullin3 function downstream of PINK1 to regulate ER clearance by influencing Rtnl1 and Atl. PINK1 regulates a change in Keap1 localization and Keap1-dependent ubiquitylation of the ER-phagy receptor Rtnl1 to facilitate ER clearance. Thus, PINK1 regulates the selective clearance of ER and mitochondria by influencing the balance of Keap1- and Parkin-dependent ubiquitylation of substrates that determine which organelle is removed by autophagy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37633267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37633267</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.008>10.1016/j.cell.2023.08.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37633267</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ruoxi Wang</dc:creator>
<dc:creator>Tina M Fortier</dc:creator>
<dc:creator>Fei Chai</dc:creator>
<dc:creator>Guangyan Miao</dc:creator>
<dc:creator>James L Shen</dc:creator>
<dc:creator>Lucas J Restrepo</dc:creator>
<dc:creator>Jeromy J DiGiacomo</dc:creator>
<dc:creator>Panagiotis D Velentzas</dc:creator>
<dc:creator>Eric H Baehrecke</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>PINK1, Keap1, and Rtnl1 regulate selective clearance of endoplasmic reticulum during development</dc:title>
<dc:identifier>pmid:37633267</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.008</dc:identifier>
</item>
<item>
<title>Circulating dipeptidyl peptidase 3 - New hope for a specific treatment to improve prognosis in cardiogenic shock?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad568. doi: 10.1093/eurheartj/ehad568. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37632844</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad568>10.1093/eurheartj/ehad568</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632844</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Janine Pöss</dc:creator>
<dc:creator>Petra Büttner</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Circulating dipeptidyl peptidase 3 - New hope for a specific treatment to improve prognosis in cardiogenic shock?</dc:title>
<dc:identifier>pmid:37632844</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad568</dc:identifier>
</item>
<item>
<title>Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad506. doi: 10.1093/eurheartj/ehad506. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37632758</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad506>10.1093/eurheartj/ehad506</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632758</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Colin Baigent</dc:creator>
<dc:creator>Rafael Sádaba</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence</dc:title>
<dc:identifier>pmid:37632758</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad506</dc:identifier>
</item>
<item>
<title>2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>In October 2021, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) jointly agreed to establish a Task Force (TF) to review recommendations of the 2018 ESC/EACTS Guidelines on myocardial revascularization as they apply to patients with left main (LM) disease with low-to-intermediate SYNTAX score (0-32). This followed the withdrawal of support by the EACTS in 2019 for the recommendations about the management of LM disease of the previous...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad476. doi: 10.1093/eurheartj/ehad476. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In October 2021, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) jointly agreed to establish a Task Force (TF) to review recommendations of the 2018 ESC/EACTS Guidelines on myocardial revascularization as they apply to patients with left main (LM) disease with low-to-intermediate SYNTAX score (0-32). This followed the withdrawal of support by the EACTS in 2019 for the recommendations about the management of LM disease of the previous guideline. The TF was asked to review all new relevant data since the 2018 guidelines including updated aggregated data from the four randomized trials comparing percutaneous coronary intervention (PCI) with drug-eluting stents vs. coronary artery bypass grafting (CABG) in patients with LM disease. This document represents a summary of the work of the TF; suggested updated recommendations for the choice of revascularization modality in patients undergoing myocardial revascularization for LM disease are included. In stable patients with an indication for revascularization for LM disease, with coronary anatomy suitable for both procedures and a low predicted surgical mortality, the TF concludes that both treatment options are clinically reasonable based on patient preference, available expertise, and local operator volumes. The suggested recommendations for revascularization with CABG are Class I, Level of Evidence A. The recommendations for PCI are Class IIa, Level of Evidence A. The TF recognized several important gaps in knowledge related to revascularization in patients with LM disease and recognizes that aggregated data from the four randomized trials were still only large enough to exclude large differences in mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37632756</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad476>10.1093/eurheartj/ehad476</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632756</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Robert A Byrne</dc:creator>
<dc:creator>Stephen Fremes</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:creator>Martin Czerny</dc:creator>
<dc:creator>Torsten Doenst</dc:creator>
<dc:creator>Jonathan R Emberson</dc:creator>
<dc:creator>Volkmar Falk</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Milan Milojevic</dc:creator>
<dc:creator>Miguel Sousa Uva</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG</dc:title>
<dc:identifier>pmid:37632756</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad476</dc:identifier>
</item>
<item>
<title>Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This study identifies cDPP3 as a novel marker of CS and increased mortality in patients with ACS. Circulating DPP3 offers prognostic information beyond established risk factors and improves early risk assessment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad545. doi: 10.1093/eurheartj/ehad545. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. This study examined the relationship of circulating DPP3 (cDPP3) with cardiogenic shock (CS) and mortality in patients presenting with acute coronary syndromes (ACS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Plasma cDPP3 levels were assessed at baseline and 12-24 hours after presentation in patients with ACS prospectively enrolled into the multicentre SPUM-ACS study (n = 4787).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Circulating DPP3 levels were associated with in-hospital CS when accounting for established risk factors including the ORBI risk score (per log-2 increase, hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.05-1.82, P = 0.021). High cDPP3 was as an independent predictor of mortality at 30 days (HR 1.87, 95% CI 1.36-2.58, P &lt; 0.001) and at 1 year (HR 1.61, 95% CI 1.28-2.02, P &lt; 0.001) after adjustment for established risk factors and the GRACE 2.0 score. Compared to values within the normal range, persistently elevated cDPP3 levels at 12-24 hours were associated with 13.4-fold increased 30-day mortality risk (HR 13.42, 95% CI 4.86-37.09, P &lt; 0.001) and 5.8-fold increased 1-year mortality risk (HR 5.79, 95% CI 2.70-12.42, P &lt; 0.001). Results were consistent across various patient subgroups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study identifies cDPP3 as a novel marker of CS and increased mortality in patients with ACS. Circulating DPP3 offers prognostic information beyond established risk factors and improves early risk assessment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37632743</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad545>10.1093/eurheartj/ehad545</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632743</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Florian A Wenzl</dc:creator>
<dc:creator>Francesco Bruno</dc:creator>
<dc:creator>Simon Kraler</dc:creator>
<dc:creator>Roland Klingenberg</dc:creator>
<dc:creator>Alexander Akhmedov</dc:creator>
<dc:creator>Stefano Ministrini</dc:creator>
<dc:creator>Karine Santos</dc:creator>
<dc:creator>Konstantin Godly</dc:creator>
<dc:creator>Julia Godly</dc:creator>
<dc:creator>David Niederseer</dc:creator>
<dc:creator>Robert Manka</dc:creator>
<dc:creator>Andreas Bergmann</dc:creator>
<dc:creator>Giovanni G Camici</dc:creator>
<dc:creator>Arnold von Eckardstein</dc:creator>
<dc:creator>Barbara Stähli</dc:creator>
<dc:creator>Olivier Muller</dc:creator>
<dc:creator>Marco Roffi</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes</dc:title>
<dc:identifier>pmid:37632743</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad545</dc:identifier>
</item>
<item>
<title>Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Under one-fifth of patients with LVEF &lt;50% who underwent MTEER for FMR in this US nationwide registry were prescribed comprehensive GDMT, with substantial variation across sites. Compared with no/single therapy, triple and double therapy prior to MTEER were independently associated with reduced risk of mortality or HFH one year after intervention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad584. doi: 10.1093/eurheartj/ehad584. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Guideline-directed medical therapy (GDMT) is recommended prior to mitral valve transcatheter edge-to-edge repair (MTEER) in patients with heart failure (HF) and severe functional mitral regurgitation (FMR). Whether MTEER is being performed on the background of optimal GDMT in clinical practice is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with left ventricular ejection fraction (LVEF) &lt; 50% who underwent MTEER for FMR from July 23, 2019 to March 31, 2022 in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry were identified. Pre-procedure GDMT utilization was assessed. Cox proportional hazards models were constructed to evaluate associations between pre-MTEER therapy (no/single, double, or triple therapy) and risk of one-year mortality or HF hospitalization (HFH).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4,199 patients across 449 sites, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, mineralocorticoid receptor antagonists, and angiotensin receptor-neprilysin inhibitor were used in 85.1%, 44.4%, 28.6%, and 19.9% prior to MTEER, respectively. Triple therapy was prescribed for 19.2%, double therapy for 38.2%, single therapy for 36.0%, and 6.5% were on no GDMT. Significant center-level variation in the proportion of patients on pre-intervention triple therapy was observed (0-61%; adjusted median odds ratio 1.48 [95% confidence interval (CI) 1.25-3.88]; P &lt; 0.001). In patients eligible for one-year follow-up (n = 2,014; 341 sites), the composite rate of one-year mortality or HFH was lowest in patients prescribed triple therapy (23.1%) compared with double (24.8%), single (35.7%), and no (41.1%) therapy (P &lt; 0.01 comparing across groups). Associations persisted after accounting for relevant clinical characteristics, with lower risk in patients prescribed triple therapy (adjusted hazard ratio [aHR] 0.73, 95% CI 0.55-0.97) and double therapy (aHR 0.69, 95% CI 0.56-0.86) prior to MTEER compared with no/single therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Under one-fifth of patients with LVEF &lt;50% who underwent MTEER for FMR in this US nationwide registry were prescribed comprehensive GDMT, with substantial variation across sites. Compared with no/single therapy, triple and double therapy prior to MTEER were independently associated with reduced risk of mortality or HFH one year after intervention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37632738</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad584>10.1093/eurheartj/ehad584</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632738</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Anubodh S Varshney</dc:creator>
<dc:creator>Miloni Shah</dc:creator>
<dc:creator>Sreekanth Vemulapalli</dc:creator>
<dc:creator>Andrzej Kosinski</dc:creator>
<dc:creator>Ankeet S Bhatt</dc:creator>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>Sameer Hirji</dc:creator>
<dc:creator>Ersilia M DeFilippis</dc:creator>
<dc:creator>Pinak B Shah</dc:creator>
<dc:creator>Mona Fiuzat</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Tsuyoshi Kaneko</dc:creator>
<dc:creator>Michael M Givertz</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry</dc:title>
<dc:identifier>pmid:37632738</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad584</dc:identifier>
</item>
<item>
<title>Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>Background: Lipoprotein(a) is a risk factor for cardiovascular events and modifies the benefit of pcsk9 inhibitors (pcsk9i). Lipoprotein(a) concentration can be measured with immunoassays reporting mass or molar concentration or a reference measurement system employing mass spectrometry. Whether the relationships between lipoprotein(a) concentrations and cardiovascular events in a high-risk cohort differ across lipoprotein(a) methods is unknown. We compared the prognostic and predictive value of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066398. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Lipoprotein(a) is a risk factor for cardiovascular events and modifies the benefit of pcsk9 inhibitors (pcsk9i). Lipoprotein(a) concentration can be measured with immunoassays reporting mass or molar concentration or a reference measurement system employing mass spectrometry. Whether the relationships between lipoprotein(a) concentrations and cardiovascular events in a high-risk cohort differ across lipoprotein(a) methods is unknown. We compared the prognostic and predictive value of these types of lipoprotein(a) tests for major adverse cardiovascular events (mace). <b>Methods:</b> The odyssey outcomes trial compared the pcsk9i alirocumab with placebo in patients with recent acute coronary syndrome (acs). We compared risk of mace in the placebo group and mace risk reduction with alirocumab according to baseline lipoprotein(a) concentration measured by siemens n-latex nephelometric immunoassay (ia-mass, mg/dl), roche tina-quant® turbidimetric immunoassay (ia-molar, nmol/l), and a non-commercial mass spectrometry-based test (ms, nmol/l). Lipoprotein(a) values were transformed into percentiles for comparative modeling. Natural cubic splines estimated continuous relationships between baseline lipoprotein(a) and outcomes in each treatment group. Event rates were also determined across baseline lipoprotein(a) quartiles defined by each assay. <b>Results:</b> Among 11,970 trial participants with results from all 3 tests, baseline median (q1, q3) lipoprotein(a) concentrations were 21.8 (6.9, 60.0) mg/dl, 45.0 (13.2, 153.8) nmol/l, and 42.2 (14.3, 143.1) nmol/l for ia-mass, ia-molar, and ms, respectively. The strongest correlation was between ia-molar and ms (r=0.990), with nominally weaker correlations between ia-mass and ms (r=0.967) and ia-mass and ia-molar (r=0.972). Relationships of lipoprotein(a) with mace risk in the placebo group were nearly identical with each test with estimated cumulative incidences differing by ≤0.4% across lipoprotein(a) percentiles, and all were incrementally prognostic after accounting for ldl-c (all spline p≤0.0003). Predicted alirocumab treatment effects were also nearly identical for each of the three tests, with estimated treatment hazard ratios (hrs) differing by ≤0.07 between tests across percentiles and nominally less relative risk reduction by alirocumab at lower percentiles for all three tests. Absolute risk reduction with alirocumab increased with increasing lipoprotein(a) measured by each test, with significant linear trends across quartiles. <b>Conclusions:</b> In patients with recent acs, three lipoprotein(a) tests were similarly prognostic for mace in the placebo group and predictive of mace reductions with alirocumab at the cohort level.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37632469</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066398>10.1161/CIRCULATIONAHA.123.066398</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632469</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael Szarek</dc:creator>
<dc:creator>Esther Reijnders</dc:creator>
<dc:creator>J Wouter Jukema</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Vera A Bittner</dc:creator>
<dc:creator>Rafael Diaz</dc:creator>
<dc:creator>Sergio Fazio</dc:creator>
<dc:creator>Genevieve Garon</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>L Renee Ruhaak</dc:creator>
<dc:creator>Markus Schwertfeger</dc:creator>
<dc:creator>Sotirios Tsimikas</dc:creator>
<dc:creator>Harvey D White</dc:creator>
<dc:creator>Ph Gabriel Steg</dc:creator>
<dc:creator>Christa Cobbaert</dc:creator>
<dc:creator>Gregory G Schwartz</dc:creator>
<dc:creator>ODYSSEY OUTCOMES Investigators</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests</dc:title>
<dc:identifier>pmid:37632469</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066398</dc:identifier>
</item>
<item>
<title>Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632455/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>Background: Hospitalization is recognized as a sentinel event in the disease trajectory of patients with heart failure (HF), but not all patients experiencing clinical decompensation are ultimately hospitalized. Outpatient intensification of diuretics is common in response to symptoms of worsening HF, yet its prognostic and clinical relevance, specifically in patient with HF with mildly reduced or preserved ejection fraction is uncertain. Methods: In this prespecified analysis of the DELIVER...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066506. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Hospitalization is recognized as a sentinel event in the disease trajectory of patients with heart failure (HF), but not all patients experiencing clinical decompensation are ultimately hospitalized. Outpatient intensification of diuretics is common in response to symptoms of worsening HF, yet its prognostic and clinical relevance, specifically in patient with HF with mildly reduced or preserved ejection fraction is uncertain. <b>Methods:</b> In this <i>prespecified</i> analysis of the DELIVER trial, we assessed the association between various non-fatal worsening HF events (those requiring hospitalization, urgent outpatient visits requiring intravenous HF therapies, and outpatient oral diuretic intensification) and rates of subsequent mortality. We further examined the treatment effect of dapagliflozin on an expanded composite endpoint of CV death, HF hospitalization, urgent HF visit, or outpatient oral diuretic intensification. <b>Results:</b> In DELIVER, 4,532 (72%) patients experienced no worsening HF event, while 789 (13%) had outpatient oral diuretic intensification, 86 (1%) required an urgent HF visit, 585 (9%) had a HF hospitalization, and 271 (4%) died of CV causes as a first presentation. Patients with a first presentation manifesting as outpatient oral diuretic intensification experienced rates of subsequent mortality that were higher (10[8-12] per 100py) than those without a worsening HF event (4[3-4] per 100py) but similar to rates of subsequent death following urgent HF visit (10[6-18] per 100py). Patients with a HF hospitalization as a first presentation of worsening HF had the highest rates of subsequent death (35[31-40] per 100py). The addition of outpatient diuretic intensification to the adjudicated DELIVER primary endpoint (CV death, HF hospitalization, or urgent HF visit) increased the overall number of patients experiencing an event from 1,122 to 1,731 (a 54% increase). Dapagliflozin reduced the need for outpatient diuretic intensification alone (HR 0.72; 95% CI: 0.64-0.82) and when analyzed as a part of an expanded composite endpoint of worsening HF or CV death (HR 0.76; 95% CI: 0.69-0.84). <b>Conclusions:</b> In patients with HF with mildly reduced or preserved ejection fraction, worsening HF requiring oral diuretic intensification in ambulatory care was frequent, adversely prognostic, and significantly reduced by dapagliflozin.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632455/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37632455</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066506>10.1161/CIRCULATIONAHA.123.066506</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632455</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Jonathan W Cunningham</dc:creator>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Rudolf A De Boer</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Felipe A Martinez</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Magnus Petersson</dc:creator>
<dc:creator>Anna-Maria Langkilde</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial</dc:title>
<dc:identifier>pmid:37632455</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066506</dc:identifier>
</item>
<item>
<title>Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828060912&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In pacemaker or ICD patients with significant RVP burden and reduced ejection fraction, upgrade to CRT-D compared to ICD therapy reduced the combined risk of all-cause mortality, heart failure hospitalisation or absence of reverse remodelling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad591. doi: 10.1093/eurheartj/ehad591. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: De novo implanted cardiac resynchronisation therapy with defibrillator (CRT-D) reduces the risk of morbidity and mortality in patients with left bundle branch block, heart failure and reduced ejection fraction (HFrEF). However, among HFrEF patients with right ventricular pacing (RVP), the efficacy of CRT-D upgrade is uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this multicentre, randomised, controlled trial, 360 symptomatic (New York Heart Association class II-IVa) HFrEF patients with a pacemaker or implantable cardioverter defibrillator (ICD), high RVP burden ≥20%, and a wide, paced QRS complex duration ≥150 ms were randomly assigned to receive CRT-D upgrade (n = 215) or ICD (n = 145) in a 3:2 ratio. The primary outcome was the composite of all-cause mortality, heart failure hospitalisation or &lt;15% reduction of left ventricular end-systolic volume assessed at 12 months. Secondary outcomes included all-cause mortality or heart failure hospitalisation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median follow-up of 12.4 months, the primary outcome occurred in 58/179 (32.4%) in the CRT-D arm vs. 101/128 (78.9%) in the ICD arm [odds ratio 0.11; 95% confidence interval (CI) 0.06-0.19; p &lt; 0.001]. All-cause mortality or heart failure hospitalization occurred in 22/215 (10%) in the CRT-D arm vs. 46/145 (32%) in the ICD arm (hazard ratio 0.27; 95% CI 0.16-0.47; p &lt; 0.001). The incidence of procedure- or device-related complications was similar between the two arms [CRT-D group 25/211 (12.3%) vs. ICD group 11/142 (7.8%)].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In pacemaker or ICD patients with significant RVP burden and reduced ejection fraction, upgrade to CRT-D compared to ICD therapy reduced the combined risk of all-cause mortality, heart failure hospitalisation or absence of reverse remodelling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828060912&v=2.17.9.post6+86293ac">37632437</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad591>10.1093/eurheartj/ehad591</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632437</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Robert Hatala</dc:creator>
<dc:creator>Jerzy K Wranicz</dc:creator>
<dc:creator>Gábor Duray</dc:creator>
<dc:creator>Csaba Földesi</dc:creator>
<dc:creator>Zoltán Som</dc:creator>
<dc:creator>Marianna Németh</dc:creator>
<dc:creator>Kinga Goscinska-Bis</dc:creator>
<dc:creator>László Gellér</dc:creator>
<dc:creator>Endre Zima</dc:creator>
<dc:creator>István Osztheimer</dc:creator>
<dc:creator>Levente Molnár</dc:creator>
<dc:creator>Júlia Karády</dc:creator>
<dc:creator>Gerhard Hindricks</dc:creator>
<dc:creator>Ilan Goldenberg</dc:creator>
<dc:creator>Helmut Klein</dc:creator>
<dc:creator>Mátyás Szigeti</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Valentina Kutyifa</dc:creator>
<dc:creator>Attila Kovács</dc:creator>
<dc:creator>Annamária Kosztin</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial</dc:title>
<dc:identifier>pmid:37632437</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad591</dc:identifier>
</item>





























</channel>
</rss>